drugset / Trial / NCT00560326

Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis

NCT00560326

Phase 2 Completed 50 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and efficacy of 0.03% tacrolimus ointment as long-term treatment in paediatric patients with atopic dermatitis.

Timeline

Start
2003-06
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.03 % Topical

Indications